Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-28413

ABSTRACT: Expression profile of etoposide-resistant MCF7 (MCF7VP) cells

PROVIDER: E-GEOD-28413 | ExpressionAtlas | 2015-08-12

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-28413-analysis-methods.tsv	Tabular
	E-GEOD-28413-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-28413-configuration.xml	Xml
	E-GEOD-28413-percentile-ranks.tsv	Tabular
	E-GEOD-28413.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 53

Similar Datasets

Homo sapiens

Project description:Expression profile of etoposide-resistant MCF7 (MCF7VP) cells

| PRJNA143253 | ENA

Homo sapiens

Project description:Expression profile of etoposide-resistant MCF7 (MCF7VP) cells with targeted RUNX2 knockdown

| PRJNA143255 | ENA

CHIP-SEQ of FOXA1 in parental MCF7 cells and tamoxifen resistant MCF7 cells

Project description:ChIP sequencing of FOXA1 in MCF7 cells and tamoxifen resistant MCF7 cells

2016-11-01 | GSE75201 | GEO

Homo sapiens

Project description:EDCs gene expression profile in MCF7 cells

| PRJNA196119 | ENA

Homo sapiens

Project description:ERα gene expression profile in MCF7 cells

| PRJNA194598 | ENA

Deciphering the Cancer Cell Resistome: Gene and microRNA Expression Signatures reveal Unique Molecular Targets for Therapeutic Intervention in Etoposide Resistant Breast Cancer

Project description:The second leading cause of cancer death for women in the U.S. is breast cancer. Moreover, a significant number of patients with breast tumors acquire resistance to drugs during therapy. To develop targeted therapeutic strategies to combat drug resistance it is essential to understand the basic molecular mechanisms through which cancer cells control sensitivity to chemotherapeutics. To identify new candidate genes and facilitate the discovery of novel drug resistance pathways, we have generated a resistance profile or ?resistome? of etoposide resistant MCF7 breast cancer cells. Differential expression of over 5000 genes (fold change > 2, P value < 0.05) indicate that several drug resistance mechanisms may be operating in these cells, including up-regulation of ABC transporter genes, down-regulation of the drug target and down-regulation of apoptotic genes. Several transcription factors such as RUNX2, SOX9, ETS1 and SMAD3 were up-regulated in the drug resistant cells. Targeted RUNX2 knockdown in the resistant cells using siRNA increased sensitivity to etoposide and also upregulated expression of pro-apoptotic genes indicating that RUNX2 could be a molecular target against etoposide resistance. Differential miRNA (microRNA) expression was observed among the drug resistant and sensitive cells suggesting that miRNA may also play a role in regulation of drug resistance. Hsa-miR-218, which targets ABCC6, was down-regulated in the drug resistant cell line. Transfection of a miR-218 mimic could down-regulate the expression of the efflux pump ABCC6 by 65% in drug resistant cells suggesting that regulation of miRNA may play an important role in etoposide resistance. long summary Refer to individual Series. This SuperSeries is composed of the following subset Series: GSE28413: Expression profile of etoposide-resistant MCF7 (MCF7VP) cells GSE28414: Expression profile of etoposide-resistant MCF7 (MCF7VP) cells with targeted RUNX2 knockdown

2011-04-08 | E-GEOD-28415 | biostudies-arrayexpress

Homo sapiens

Project description:Gene expression profile of NR2E3 in MCF7 cells

| PRJNA118229 | ENA

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

2011-01-29 | GSE19777 | GEO

VGLL1 drives therapy resistance in estrogen receptor positive breast cancer [ChIP-Seq]

Project description:The transcriptional activity of the TEAD4 trascription factor requires co-activators. In this study we found that the expression of the TEAD coactivator VGLL1 is repressed in estrogen receptor positive breast cancer but upon resistance to endocrine threapies VGLL1 is expressed to high levels. To elucidate the importance of the coactivator VGLL1 in breast cancer cells resistant to endocrine therapies and to identify the VGLL1 target genes, we performed ChIP-seq for VGLL1 in MCF7 breast cancer cells resistant to fulvestrant (FULVR) and ChiP-seq for TEAD4 in FULVR cells and the isogenic MCF7 cells.

2023-12-05 | GSE216525 | GEO

Antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells

Project description:Full title: Expression data from antisense miRNA-221/222 (si221/222) and control inhibitor (GFP) treated fulvestrant-resistant breast cancer cells The expression of miR-221/222 were found to be upregulated in fulvestrant resistant breast cancer cells MCF7-FR compared to its drug-sensitive counterpart MCF7. To investigate the role of miR-221/222 in acquired resistance to fulvestrant, we lowered the level of miR-221/222 in MCF7-FR cells using miRNA inhibitors (antagomirs), and compared gene expression profiles before and after treatment. Fulvestrant-resistant breast cancer cells MCF7-FR (originated from drug-sentitive breast cancer model cell line MCF7) were transient-transfected by antigomirs targeting miR221 or miR222 (i.e. si221, si222). All three cell lines, MCF7-FR, siR221, siRNA222 were subjected to gene expression profiling.

2011-01-29 | E-GEOD-19777 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data